GlassScriptPhysician profile
Laleh A Bedocs
NPI 1952483828
$10,564.62
in general payments reported to CMS, 2019-2025
37 companies · $2,741 in 2025
The $2,741 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $536 · 2021: $941 · 2022: $1,634 · 2023: $1,123 · 2024: $2,466 · 2025: $2,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,183 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,183.46 |
| Education | $147.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,755.05 | 2019-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $934.02 | 2019-2025 | |
| Lilly USA, LLC | $840.33 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $799.64 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Galderma Laboratories, L.P. | $582.04 | 2019-2025 | Nemluvio, Aklief |
| Ucb, INC. | $555.43 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $481.03 | 2019-2025 | |
| Janssen Biotech, INC. | $439.29 | 2019-2025 | Tremfya |
| Epi Health, LLC | $395.87 | 2019-2022 | |
| Dermavant Sciences, INC. | $368.05 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $348.78 | 2022-2024 | Sotyktu |
| Amgen INC. | $319.08 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $316.86 | 2023-2025 | Adbry, Anzupgo, Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $307.63 | 2020-2025 | Cabtreo, Jublia, Arazlo |
| Incyte Corporation | $277.24 | 2022-2024 | Opzelura |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $275.92 | 2024-2025 | Vtama |
| Journey Medical Corporation | $228.72 | 2019-2022 | |
| Genzyme Corporation | $208.59 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $143.36 | 2020-2025 | Libtayo, Dupixent |
| Vyne Pharmaceuticals INC. | $129.89 | 2020-2021 | |
| Celgene Corporation | $108.98 | 2019 | |
| Chiesi USA, INC. | $93.26 | 2024-2025 | Filsuvez |
| Dermira, INC. | $88.33 | 2020-2021 | |
| Convatec INC. | $81.68 | 2024-2025 | |
| Almirall LLC | $79.37 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $73.02 | 2019-2025 | |
| Strata Skin Sciences, INC. | $69.21 | 2024-2025 | Xtrac |
| Mimedx Group, INC. | $48.99 | 2025 | |
| Lnhc, INC | $48.92 | 2025 | Zelsuvmi |
| Prugen, INC. Pharmaceuticals | $35.88 | 2019 | |
| Biocon Biologics INC | $24.62 | 2024 | Hulio |
| Cipher Pharmaceuticals US LLC | $21.37 | 2025 | Natroba, Spinosad |
| Verrica Pharmaceuticals INC. | $20.34 | 2023 | Ycanth |
| Kyowa Kirin, INC. | $17.53 | 2024 | Poteligeo |
| Arcutis Biotherapeutics, INC. | $16.36 | 2025 | Zoryve |
| Promius Pharma LLC | $15.67 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $14.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laleh Bedocs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.